Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - caffeine citrate - oral solution - caffeine citrate 10 mg/ml - psychoanaleptics

United States - English - NLM (National Library of Medicine)

armas pharmaceuticals inc. - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate injection is indicated for the treatment of apnea of prematurity. caffeine citrate injection is contraindicated in patients who have demonstrated hypersensitivity to any of its components.

United States - English - NLM (National Library of Medicine)

micro labs limited - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine  citrate is indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. caffeine citrate is contraindicated in patients who have demonstrated hypersensitivity to any of its components. caffeine citrate oral solution each bottle (vial) of caffeine citrate oral solution contains a total of 60 mg of caffeine citrate in 3 ml (20 mg/ml). information and instructions for use this leaflet tells you about caffeine citrate oral solution (kaf-een sit-rate) and how to give it to your baby.  read the following information before giving this medicine to your baby.  completely discuss caffeine citrate oral solution with your baby’s doctor.  continue to discuss any questions you have about this medicine at your baby’s checkups. after you remove your baby’s dose, throw away the open bottle (vial) and all medicine left in it .  use each vial of caffeine citrate oral solution for only one dose.  there will be extra medicine left in the vial after one dose is remo

United States - English - NLM (National Library of Medicine)

armas pharmaceuticals inc. - caffeine citrate (unii: u26eo4675q) (caffeine - unii:3g6a5w338e) - caffeine citrate is indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. caffeine citrate is contraindicated in patients who have demonstrated hypersensitivity to any of its components. caffeine citrate oral solution each bottle (vial) of caffeine citrate oral solution contains a total of 60 mg of caffeine citrate in 3 ml (20 mg/ml). information and instructions for use this leaflet tells you about caffeine citrate oral solution (kaf-een sit-rate) and how to give it to your baby.  read the following information before giving this medicine to your baby.  completely discuss caffeine citrate oral solution with your baby’s doctor.  continue to discuss any questions you have about this medicine at your baby’s checkups. after you remove your baby’s dose, throw away the open bottle (vial) and all medicine left in it .  use each vial of caffeine citrate oral solution for only one dose.  there will be extra medicine left in the vial after one dose is remov

Kenya - English - Pharmacy and Poisons Board

macarthy laboratories ltd t/a martindale pharma bamptom road harold hill romford essex rm3 8ug - caffeine citrate - solution for injection - 10mg/ml - caffeine

Kenya - English - Pharmacy and Poisons Board

caffeine citrate - oral drops - 20mg/ml - caffeine

Australia - English - Department of Health (Therapeutic Goods Administration)

fit-bioceuticals limited - caffeine,ribose,ubidecarenone -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 832.5 mg (equivalent: ciprofloxacin, qty 750 mg) - tablet, film coated - excipient ingredients: maize starch; sodium starch glycollate type a; purified talc; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 555 mg (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate type a; purified talc; maize starch; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ciprofloxacin hydrochloride, quantity: 277.5 mg (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: maize starch; colloidal anhydrous silica; microcrystalline cellulose; purified talc; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - the treatment of infections caused by susceptible organisms in the conditions listed below: - urinary tract infections - gonorrhoeal urethritis and cervicitis - gastroenteritis, - bronchial infections - skin and skin structure infections - bone and joint infections - chronic bacterial prostatitis of mild to moderate severity. note: 1. typhoid and paratyphoid infections and infections due to multiresistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in case with gram- positive infections, such as pneumonia due to streptococcus pneumoniae. 3. chronic bacterial prostatitis should be demonstrated by microbiological evidence localising infection to the prostate. strains of neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to determine organism susceptibility to ciprofloxacin and after treatment as warranted by the clinical condition. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.